Autoimmunity and Neuroinflammation in Fibromyalgia

Fibromyalgia (FM) may be an autoimmune disease, where your immune system attacks healthy cells by mistake. For years, the evidence seemed to point away from that. This issue is still far from decided, but opinion may be swaying back toward autoimmunity.

Some research suggests FM may be an autoimmune disease involving neuroinflammation, an inflammatory response within the brain and spinal cord, and small-fiber neuropathy, which is weakness and pain from nerve damage.

That hypothesis isn’t getting widespread acceptance in the medical community, though.

This article looks at what this research says; the evidence for autoimmunity, neuroinflammation, and small-fiber neuropathy; why not all inflammation is created equal; and why these findings—if accurate—are important.

Is Fibromyalgia an Autoimmune Disease?

For decades, fibromyalgia’s very existence was controversial. But not anymore. Early on, some doctors who believed in FM classified it as “arthritis-like.”

Many medical experts suspected autoimmunity because of the condition’s similarities to known autoimmune diseases such as lupus, Sjögren’s syndrome, rheumatoid arthritis, and multiple sclerosis.

However, early research failed to turn up the hallmarks of autoimmune disease, including:

  • Damage from the immune system attack
  • Inflammation as part of the immune and healing processes
  • Autoantibodies (immune system proteins that target a part of your body)

What Is Autoimmunity?

Autoimmunity is an immune system turned against its body. Your immune system mistakes a healthy type of cell or tissue in your body for a dangerous pathogen, like a virus or bacterium. It then attacks and tries to destroy the target. This leads to tissue damage, inflammation, and other symptoms.

Later, FM was considered a pain condition that was believed to be neurological or neuroimmune. The term central sensitivity syndrome developed as an umbrella term for FM and related illnesses, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), irritable bowel syndrome (IBS), and migraine.

Now, FM is seen as a complex, multi-symptom illness. What’s more, some evidence suggests it actually isn’t missing those hallmarks of autoimmunity:

  • Damage? Yes, small-fiber neuropathy.
  • Inflammation? Yes, in the brain and nerves of the spinal cord (central nervous system).
  • Autoantibodies? Yes, several of them.


Fibromyalgia has always borne a striking resemblance to autoimmune diseases. Research published in 2019 laid out the many factors they have in common:

  • They’re often triggered by trauma and infection.
  • Various pathogens may increase your risk (Epstein-Barr virus, herpes simplex virus, hepatitis C).
  • They can develop soon after vaccination, silicone breast implantation, or mineral oil injection.
  • They’re more common in women.
  • They involve genetic differences known to predispose you to autoimmunity.
  • They often occur alongside other autoimmune diseases.
  • Evidence shows activation of the adaptive immune system.


Researchers believe they may have found the smoking gun of autoimmunity in FM as well. They discovered that several autoantibodies were unusually high in people with FM, including those for:

  • Serotonin: A neurotransmitter (chemical messenger) and hormone known to be dysregulated in FM
  • Gangliosides: A type of molecule in the brain linked to several neurodegenerative conditions, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS)
  • Phospholipids: Molecules that make up protective barriers around cells and regulate certain cellular processes
  • Smooth muscle: Muscles located in organs, under involuntary control
  • Striated muscle: Skeletal muscles, under voluntary control
  • Moisture-producing glands: The same autoantibodies as in Sjögren’s syndrome which affect moisture-producing glands in the mucous membranes that line organs and the inside of your body
  • Thyroid gland: The same autoantibodies as in Hashimoto’s thyroiditis, an autoimmune thyroid disease

None of these were found in every person with FM. Rates ranged from about 19% to 73%. 

Gangliosides may be an important aspect of FM autoimmunity. They’re believed to be involved in small-fiber neuropathy.

Autoantibody Rates, FM Studies
Serotonin 73%
Gangliosides 71%
Phospholipids 54%
Smooth muscle 55%
Striated muscle 40%
Sjögren’s syndrome antibodies 32%
Thyroid gland 19%
*Among those with Sjögren’s syndrome

Giving Fibromyalgia to Mice

In a groundbreaking 2021 study, researchers took antibodies (immunoglobulin G, IgG) from people with FM and injected them into mice. The mice then:

  • Developed hypersensitivity to pain and cold
  • Became less active
  • Lost paw grip strength
  • Lost nerve fibers in the skin

Researchers say the FM IgG appeared to target white-matter brain cells (glia), gray-matter brain cells (neurons), and certain nerve fibers. This shows how immune system activity can cause neurological symptoms.

The ability to transfer FM like this is nothing short of revolutionary. On top of providing evidence about what’s causing symptoms, it could point to new diagnostic tests and treatments.

Diagnosis and Treatment

If more research validates findings of autoimmunity in fibromyalgia, it could lead to diagnostic tests. For a condition that’s currently a diagnosis of exclusion, that’s an important change.

Many immunosuppressive drugs for autoimmune diseases are already on the market. That greatly expands treatment options, especially since the drugs could be used off-label right away.

It remains to be seen whether current immunosuppressants are safe and effective for FM.


Several studies have now confirmed neuroinflammation in fibromyalgia. Some also have looked at where it is in the brain and what may be driving it.

Inflammation is a complex immune response to injury and infection. It’s a necessary function. But when it becomes chronic, inflammation causes tissue damage. It’s especially harmful in the nervous system.

Areas Impacted by Neuroinflammation in Fibromyalgia

Verywell / Shideh Ghandeharizadeh

The nervous system and immune system work together to create neuroinflammation. FM research links several cells and one molecule to the process.

Neurological components include:

  • Microglia: A type of cell that’s part of the nervous system’s dedicated immune system
  • Astrocytes: Cells of the brain and spinal cord involved in information processing and implicated in neurodegenerative disease
  • Oligodendrocytes: White-matter cells that form myelin sheaths around nerves and regulate neuronal circuits
  • Brain-derived neurotrophic factor (BDNF): A key molecule involved in learning and memory, also tied to aging and brain-related disease

Immune system components include:

  • Mast cells: A type of white blood cell that helps keep the immune system in balance
  • Chemokines: Immune cells that attract white blood cells to sites of infection
  • Pro-inflammatory cytokines: Immune system proteins that drive the inflammatory response
  • Interleukins: Proteins that regulate immune response
  • Tumor necrosis factor alpha (TNFα): A type of cytokine involved in inflammation and cell death
  • Macrophages: Tissue resident immune cells usually found at the site of infection
  • T-cells: Specialized immune cells that target proteins identified (or misidentified) as foreign

A 2021 study looked at where brain inflammation is in FM. Researchers found several areas with abnormal inflammation compared with healthy people in the control group.

Some of these areas play roles in functions that are often dysregulated in people with FM. They include:

  • Primary somatosensory cortex: Processes physical sensations, especially touch
  • Primary motor cortex: Skilled movement
  • Superior frontal gyrus: Higher cognitive function and working memory
  • Left superior parietal gyrus: Attention, spatial perception
  • Left precuneus: Memory-based tasks, episodic memory recall
  • Left medial frontal gyrus: Development of literacy

They also found abnormally low inflammation-related activity in the:

  • Medulla: Relays messages between the brain and spinal cord, regulates cardiovascular and respiratory systems (heart and lungs)
  • Amygdala: Drives the stress and fear response (fight-or-flight)
  • Left superior temporal gyrus: Language processing, remembering what you’ve just heard

Neuroinflammation in the amygdala, left medial frontal, and left superior parietal gyri was associated with higher pain scores. Neuroinflammation in the left amygdala, left medial frontal, and left superior frontal gyri was associated with higher stress responses, which included measures of fatigue, tension, frustration, depression, somatization, and aggression.

A Different Type of Inflammation

Neuroinflammation has different effects than “typical” inflammation in the joints and soft tissues. Typical inflammation causes pain in many conditions, such as arthritis and multiple sclerosis.

When tissues expand beyond their normal size, they cause pain by putting pressure on surrounding structures. Arthritic fingers hurt because they’re inflamed.

Neuroinflammation doesn’t cause the same issues. Instead, it causes neurological problems that lead to neurological symptoms.

FM pain is believed to come from central sensitization, which is a heightened response to pain in the central nervous system. Research suggests neuroinflammation is behind central sensitization.

So, regardless of neuroinflammation, your FM pain isn’t caused by tissue inflammation and therefore can’t be treated in the same way.

Diagnosis and Treatment

Inflammatory markers for fibromyalgia tend to be slightly elevated. But the cells and molecules involved in the neuroinflammation of FM may provide new diagnostic markers to look for.

Drugs that suppress microglia and astrocytes may be useful for treating neuroinflammation. They include:

Other existing treatments for neuroinflammation include: 

Several other drugs are under development for neuroinflammation, most of them developed as potential Parkinson’s disease treatments. Anti-inflammatory drugs are often prescribed for neuroinflammatory disease as well. However, they’ve historically been considered ineffective for FM pain.

Small-Fiber Neuropathy

Small-fiber neuropathy (SFN) is nerve damage that’s only in the small sensory nerves of the skin. It’s probably best known in relation to type 2 diabetes.

As in FM, the pain comes and goes and is described as:

  • Stabbing
  • Burning
  • Tingling
  • Itchy

Also like FM, SFN involves the abnormal pain types hyperalgesia and allodynia. Hyperalgesia makes your pain signals more intense, basically “turning up the volume” of pain. Allodynia makes things hurt that shouldn’t, like a loose waistband or a hand rubbing lightly against your skin.

SFN and fibromyalgia also have these symptoms in common:

FM research suggests some damaged nerves are part of anti-inflammatory processes. That provides another explanation for neuroinflammation.

Typical SFN vs. Fibromyalgia SFN

In most SFN, pain begins in the feet and then moves upward. It’s been thought that only a small percentage of SFN begins with body-wide pain. The association between SFN and FM, which by definition includes body-wide pain, could change that belief.

Diagnosis and Treatment

The typical diagnostic test for SFN is a skin punch biopsy. A small amount of skin is removed with a circular tool and examined under a microscope. The focus is on nerve fiber density in the skin.

SFN is treatable, and small nerves continue to grow throughout life. That means they can repair damage.

Standard SFN treatments are already heavily used for fibromyalgia. They include:

In a pilot study, treatment with intravenous immunoglobulin (IVIg) has been shown to improve SFN in FM. This treatment is known to be effective against autoimmune-related neuropathy. Biopsies confirmed that nerves showed less damage after treatment.

Ganglioside autoimmunity may suggest treatment options as well. Gangliosides are suspected of being involved with diabetes-related small-fiber neuropathy. Some early animal research has suggested that ganglioside-targeted treatments may improve neuropathic pain.

Currently, researchers are working on drugs called ganglioside GM3 synthase inhibitors. Evidence suggests that these may work as both oral medication and topical treatments.


Research has uncovered evidence that FM is an autoimmune disease. Neuroinflammation and small-fiber neuropathy appear to be important elements of it. Autoantibodies could provide diagnostic markers for FM. Immunosuppressants may be treatment options. Neuroinflammation and SFN also offer potential diagnostic markers. Existing treatments are on the market. Some experimental drugs are in the works as well.

A Word From Verywell

Recent findings are finally separating fibromyalgia from a past full of controversy, disbelief, and even scorn. While diagnostic markers and treatment options are all important advances, just having validation is something many people with FM have—for years or even decades—waited for. Advances in research could also potentially expand treatment options for people living with FM.

Frequently Asked Questions

  • Can fibromyalgia cause brain damage?

    Fibromyalgia isn’t classified as a neurodegenerative disease (one that destroys parts of the brain). However, it’s possible that the immune and inflammatory processes now being uncovered can cause damage to certain cells or regions in the brain. FM has long been associated with reduced gray matter in the brain. However, some research suggests it’s due to low water content and not neurodegeneration.

  • Can autoimmune disease be cured?

    No, autoimmune disease currently can’t be cured. It can be successfully treated, though. Treatment for most autoimmune disease is aimed at suppressing activity in the immune system. Other treatments may help with symptoms specific to each disease.

  • What does a fibromyalgia flare feel like?

    An FM flare is a more intense period of FM symptoms. Pain and fatigue get significantly worse. You may be lethargic, unable to focus or absorb information, and have a harder time sleeping. However, FM has so many potential symptoms that it’s hard to say how one person’s flare may compare with someone else’s.

  • Why does FM hurt so bad?

    Fibromyalgia hurts so bad because neuropathy is often intensely painful. Allodynia means the nervous system interprets normal signals as painful. Hyperalgesia “turns up the volume” on pain signals, worsening pain from neuropathy, allodynia, and any other sources (such as a bad back or injury).

28 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Ryabkova VA, Churilov LP, Shoenfeld Y. Neuroimmunology: what role for autoimmunity, neuroinflammation, and small fiber neuropathy in fibromyalgia, chronic fatigue syndrome, and adverse events after human papillomavirus vaccination? Int J Mol Sci. 2019;20(20):5164. doi:10.3390/ijms20205164

  2. Inanici F, Yunus MB. History of fibromyalgia: past to present. Curr Pain Headache Rep. 2004;8(5):369-378. doi:10.1007/s11916-996-0010-6

  3. Sipione S, Monyror J, Galleguillos D, Steinberg N, Kadam V. Gangliosides in the brain: physiology, pathophysiology and therapeutic applications. Front Neurosci. 2020;14:572965. doi:10.3389/fnins.2020.572965

  4. Suk JH, Lee JH, Kim JM. Association between thyroid autoimmunity and fibromyalgia. Exp Clin Endocrinol Diabetes. 2012;120(7):401-404. doi:10.1055/s-0032-1309008

  5. Menichella DM, Jayaraj ND, Wilson HM, et al. Ganglioside GM3 synthase depletion reverses neuropathic pain and small fiber neuropathy in diet-induced diabetic mice. Mol Pain. 2016;12:1744806916666284. doi:10.1177/1744806916666284

  6. Goebel A, Krock E, Gentry C, et al. Passive transfer of fibromyalgia symptoms from patients to miceJ Clin Invest. 2021;131(13):e144201. doi:10.1172/JCI144201

  7. Skaper SD, Facci L, Zusso M, Giusti P. An inflammation-centric view of neurological disease: beyond the neuron [published correction appears in Front Cell Neurosci. 2020;13:578]. Front Cell Neurosci. 2018;12:72. doi:10.3389/fncel.2018.00072

  8. Jung C, Ichesco E, Ratai EM, et al. Magnetic resonance imaging of neuroinflammation in chronic pain: a role for astrogliosis? Pain. 2020;161(7):1555-1564. doi:10.1097/j.pain.0000000000001815

  9. Nijs J, Loggia ML, Polli A, et al. Sleep disturbances and severe stress as glial activators: key targets for treating central sensitization in chronic pain patients? Expert Opin Ther Targets. 2017;21(8):817-826. doi:10.1080/14728222.2017.1353603

  10. Bäckryd E, Tanum L, Lind AL, Larsson A, Gordh T. Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. J Pain Res. 2017;10:515-525. doi:10.2147/JPR.S128508

  11. Zhang X, Hartung JE, Bortsov AV, et al. Sustained stimulation of β2- and β3-adrenergic receptors leads to persistent functional pain and neuroinflammation. Brain Behav Immun. 2018;73:520-532. doi:10.1016/j.bbi.2018.06.017

  12. Sommer C, Leinders M, Üçeyler N. Inflammation in the pathophysiology of neuropathic pain. Pain. 2018;159(3):595-602. doi:10.1097/j.pain.0000000000001122

  13. Seo S, Jung YH, Lee D, et al. Abnormal neuroinflammation in fibromyalgia and CRPS using [11C]-(R)-PK11195 PET. PLOS ONE. 2021;16(2):e0246152. doi:10.1371/journal.pone.0246152

  14. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread painAnesthesiology. 2018;129(2):343-366. doi:10.1097/ALN.0000000000002130

  15. Tennant F. Microglial modulators: a new therapeutic class. Pract Pain Manag.

  16. Liu CY, Wang X, Liu C, Zhang HL. Pharmacological targeting of microglial activation: new therapeutic approach. Front Cell Neurosci. 2019;13:514. doi:10.3389/fncel.2019.00514

  17. Camara ML, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H, Baune BT. Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology. 2015;40(2):502-512. doi:10.1038/npp.2014.199

  18. Abd-Ellatief RB, Mohamed HK, Kotb HI. Reactive astrogliosis in an experimental model of fibromyalgia: effect of dexmedetomidine. Cells Tissues Organs. 2018;205(2):105-119. doi:10.1159/000488757

  19. Mueller C, Ness TJ, Younger JW. Low-dose dextromethorphan for the treatment of fibromyalgia pain: results from a longitudinal, single-blind, placebo-controlled pilot trial. J Pain Res. 2021;14:189-200. doi:10.2147/JPR.S285609

  20. D’Amico R, Fusco R, Siracusa R, et al. Inhibition of p2x7 purinergic receptor ameliorates fibromyalgia syndrome by suppressing nlrp3 pathway. Int J Mol Sci. 2021;22(12):6471. doi:10.3390/ijms22126471

  21. Royds J, Conroy MJ, Dunne MR, McCrory C, Lysaght J. An investigation into the modulation of T cell phenotypes by amitriptyline and nortriptyline. Eur Neuropsychopharmacol. 2020;31:131-144. doi:10.1016/j.euroneuro.2019.12.106

  22. Clinical Pain Advisor. Neuroinflammation: treating the underlying cause of chronic, severe pain.

  23. Johns Hopkins Medicine. Small fiber sensory neuropathy.

  24. MedlinePlus. Small fiber neuropathy.

  25. Oaklander AL, Nolano M. Scientific advances in and clinical approaches to small-fiber polyneuropathy: a review [published correction appears in JAMA Neurol. 2019;76(12):1520]. JAMA Neurol. 2019;76(10):1240-1251. doi:10.1001/jamaneurol.2019.2917

  26. Metyas S, Chen C, Quismorio A, Abdo N, Kamel K. Improvement of nerve fiber density in fibromyalgia patients treated with ivig. Curr Rheumatol Rev. 2020;16(4):280-284. doi:10.2174/1573397115666191106120622

  27. Yamanaka K, Takahashi Y, Azuma Y, Hantani Y. Assay development and screening for the identification of ganglioside gm3 synthase inhibitors. Biochemistry. 2020;59(12):1242-1251. doi:10.1021/acs.biochem.0c00055

  28. Pomares FB, Funck T, Feier NA, et al. Histological underpinnings of grey matter changes in fibromyalgia investigated using multimodal brain imagingJ Neurosci. 2017;37(5):1090-1101. doi:10.1523/JNEUROSCI.2619-16.2016

By Adrienne Dellwo
Adrienne Dellwo is an experienced journalist who was diagnosed with fibromyalgia and has written extensively on the topic.